Special Issue

Inoviruses

Message from the Guest Editors

Inoviruses are filamentous bacteriophages that cause a chronic infection of their bacterial host. Significant research has been conducted into the classic inovirus M13 for its molecular biology and biotechnology applications. However, there is limited research into the impact of inoviruses on the fitness and virulence of multidrug-resistant bacterial pathogens. In this Special Issue, we aim to gather contributions that advance the current knowledge on the role and impact of these unique understudied phages on bacterial fitness, microbial pathogenesis, and host–pathogen interactions. Manuscripts of original research, reviews, mini-reviews, commentary and perspectives on the following areas of inovirus study are particularly welcome:

- Identification of novel inoviruses, including the use of viral metagenomics approach
- Contribution to bacterial pathogenesis
- Inoviruses as virulence factors
- Prevalence in multidrug-resistant pathogens
- Targets for vaccine development (pre-clinical studies)
- Impact on bacterial fitness
- Other inoviruses research areas

Guest Editors

Dr. Danielle Peters

Human Health and Therapeutics Research Center (HHT), National Research Council Canada, Ottawa, ON, Canada

Dr. Wangxue Chen

Human Health and Therapeutics Research Center (HHT), National Research Council Canada, Ottawa, ON, Canada

Deadline for manuscript submissions

closed (24 December 2024)

Viruses

an Open Access Journal by MDPI

Impact Factor 3.5
CiteScore 7.7
Indexed in PubMed

mdpi.com/si/164242

Viruses
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
viruses@mdpi.com

mdpi.com/journal/viruses

Viruses

an Open Access Journal by MDPI

Impact Factor 3.5
CiteScore 7.7
Indexed in PubMed

mdpi.com/journal/viruses

MDPI

About the Journal

Message from the Editor-in-Chief

You are invited to contribute a research article or a comprehensive review for consideration and publication in *Viruses* (ISSN 1999-4915). *Viruses* is published in open access format—research articles, reviews and other content are released on the internet immediately after acceptance. The scientific community and the general public have unlimited free access to the content as soon as it is published. As an open access journal, *Viruses* is supported by the authors or their institutes by payment of article processing charges (APC) for accepted papers. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Dr. Eric O. Freed
HIV Dynamics and Replication Program, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702-1201, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, and other databases.

Journal Rank:

JCR - Q2 (Virology) / CiteScore - Q1 (Virology/Infectious Diseases)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17.2 days after submission; acceptance to publication is undertaken in 2.7 days (median values for papers published in this journal in the second half of 2025).